Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?

Key Takeaways Novo Nordisk unveiled limited-time $199 pricing for new Wegovy and Ozempic self-pay patients.Pricing shifts follow an agreement to expand U.S. access and move patients toward FDA-approved treatments.Novo Nordisk seeks to regain share from Lilly as compounded products pressure demand and guidance cuts.Last week, Novo Nordisk (NVO) announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per m ...